Tuoxin Pharmaceutical: Special report on the storage and use of funds raised in the previous round

Tuoxin Pharmaceutical Group Co., Ltd.

Special report on the storage and use of funds raised last time

In accordance with the relevant provisions of the China Securities Regulatory Commission's "Guidelines for the Application of Regulatory Rules - Issuance Category No. 7", the company will report the use of the previous raised funds as of December 31, 2025 as follows.

1. Previous fundraising situation

(1) The amount of funds raised last time and the time when the funds will be received

As approved by the China Securities Regulatory Commission's Securities Regulatory Commission Document No. [2021] 3021, the company publicly issued 31,500,000 RMB ordinary shares (A shares) to the public on October 27, 2021. The issue price per share was 19.11 yuan, and the total funds raised were RMB 60 1,965,000.00 yuan, and the raised funds after deducting the sponsor and underwriting fee of 43,159,754.72 yuan were 558,805,245.28 yuan. The lead underwriter Zhongtian Guofu Securities Co., Ltd. remitted it to the company’s raised funds supervision account on October 22, 2021. After deducting intermediary fees and other issuance fees of 15,531,135.51 yuan (excluding value-added tax), the actual amount of funds raised this time was 543,274,109.77 yuan. The availability of the above-mentioned raised funds has been verified by Zhongshen Zhonghuan Accounting Firm (Special General Partnership) on October 22, 2021, and issued a "Capital Verification Report" (Zhonghuan Yanzi (2021) No. 2110001).

(2) The deposit of funds raised in the previous time in the special account

In accordance with the provisions of relevant laws and regulations, and following the principles of standardization, safety, efficiency and transparency, the company has formulated the "Raised Funds Management System", which clearly stipulates the storage, approval, use, management and supervision of raised funds to ensure the standardized use of raised funds in the system.

In October 2021, the company and the sponsoring institution Zhongtian Guofu Securities Co., Ltd. signed the "Raised Funds Supervision Agreement" with Bank of China Co., Ltd. Xinxiang Branch, Shanghai Pudong Development Bank Co., Ltd. Xinxiang Branch, and Zhongyuan Bank Co., Ltd. Co., Ltd. Xinxiang Branch opened a special account for raised funds (account number: 11710078801200001792), and the business department of Xinxiang Branch of Zhongyuan Bank Co., Ltd. opened a special account for raised funds (account number: 11710078801200001792). No.: 410701010100088803), Xinxiang Development Zone Branch of Zhongyuan Bank Co., Ltd. opened a special account for raised funds (account number: 410716010100037701).

In November 2021, the company and its wholly-owned subsidiary Xinxiang Pharmaceutical Co., Ltd., which specifically implemented the fundraising project, and the sponsoring institution Zhongtian Guofu Securities Co., Ltd., Zhengzhou Branch of China CITIC Bank Co., Ltd. and Shanghai Pudong Development Bank

Xinxiang Branch of Xinxiang Pharmaceutical Co., Ltd. signed the "Supervision Agreement on Raised Funds" respectively. Xinxiang Pharmaceutical Co., Ltd.

Xinxiang Fenghua Street Branch of China Credit Bank Co., Ltd. opened a special account for raised funds (account number:

8111101012101351265), Shanghai Pudong Development Bank Co., Ltd. Xinxiang Branch opened a special fund-raising project

Account (account number: 11710078801000001798).

In August 2022, the company and its wholly-owned subsidiary Xinxiang Jingquan Biotechnology Co., Ltd. will implement the fundraising project.

Signed the Fund Raising Agreement with Bank of China Co., Ltd. Xinxiang Branch and the sponsoring institution Zhongtian Guofu Securities Co., Ltd.

"Golden Tripartite Supervision Agreement", set up a special account for raised funds at the Xinxiang County Branch of Bank of China Co., Ltd. (account number:

249482045871).

In March 2023, the company and its subsidiaries that specifically implemented the fundraising project, Henan Nucleoside Research Institute Co., Ltd.,

Xiangshi Nucleoside Industry Research Institute Co., Ltd. and Shanghai Pudong Development Bank Co., Ltd. Xinxiang Branch and sponsor respectively

The institution Zhongtian Guofu Securities Co., Ltd. signed the "Tripartite Supervision Agreement on Raised Funds", respectively, in Shanghai Pudong Development Bank

Xinxiang Dongming Avenue Branch of Xinxiang Bank Co., Ltd. established a raised fund account (account number: 11740078801200000084,

11740078801500000087).

As of December 31, 2025, the deposit status of the company's previous raised funds in the bank account is as follows:

Bank name Bank account number Initial deposit amount Balance Bank of China Co., Ltd. Xinxiang County Branch 255977511859 100,000,000.00 Canceled account Xinxiang Branch of Shanghai Pudong Development Bank Co., Ltd. 11710078801200001792 235,456,400.00 Canceled account Xinxiang Branch Business Department of Zhongyuan Bank Co., Ltd. 410701010100088803 60,000,000.00 Canceled account at Xinxiang Development Zone Branch of Zhongyuan Bank Co., Ltd. 410716010100037701 163,348,845.28 Canceled account at Xinxiang Fenghua Street Branch of CITIC Bank Co., Ltd. 8111101012101351265 Canceled account: Xinxiang Branch of Shanghai Pudong Development Bank Co., Ltd. 11710078801000001798 Canceled account: Xinxiang County Branch of Bank of China Co., Ltd. 249482045871 Canceled account: Xinxiang Dongming, Shanghai Pudong Development Bank Co., Ltd.

11740078801200000084 Closed Avenue Branch

Shanghai Pudong Development Bank Co., Ltd. Xinxiang Dongming

11740078801500000087 Closed Avenue Branch

Total 558,805,245.28

2. Description of the actual use of funds raised last time

(1) Comparison table of usage of funds raised last time

Please see Appendix 1 of this report for a comparison table of the use of funds raised in previous rounds.

(2) Explanation of changes in actual investment of funds raised last time

1. Changes in investment projects with previously raised funds

There were no changes in investment projects when the company raised funds last time.

2. Changes in the implementation entity, implementation method and implementation location of the previous investment project with raised funds

On February 9, 2022, the 10th meeting of the company's fourth board of directors and the sixth meeting of the fourth board of supervisors reviewed and approved the "Proposal on Changing the Implementation Location of Some Fund-raising Projects" and agreed to change the implementation location of the "Tuoxin Pharmaceutical Research Institute Construction Project" from the original "the company's existing industrial land - the southeast corner of No. 398 Jingquan West Road, Xinxiang High-tech Development Zone" to "east of Fenghua Street in Xinxiang City and north of planned Jingquan Road". The company's independent directors issued independent opinions in agreement, and the sponsor issued an unobjectionable verification opinion.

On May 23, 2022, the 13th meeting of the company's fourth board of directors, the ninth meeting of the fourth board of supervisors, and the fourth extraordinary shareholders' meeting of 2022 held on June 9, 2022, reviewed and approved the "Proposal on Changing the Implementation Location, Implementation Method and Purchase of Assets for Some Fund-raising Projects" and agreed to the company's changes. The implementation location and implementation method of the "Tuoxin Medical Research Institute Construction Project", a part of the investment project with raised funds, was changed from "east of Fenghua Street, Xinxiang City, north of planned Jingquan Road" to "Neighborhood No. 24, Xinxiang Development Zone", and the implementation method was changed from the self-construction model to the purchase of real estate and transformation according to the company's needs. The company's independent directors issued independent opinions in agreement, and the sponsor issued an unobjectionable verification opinion.

On January 16, 2023, the 20th meeting of the company's fourth board of directors, the fourteenth meeting of the fourth board of supervisors, and the first extraordinary shareholders' meeting of 2023 on February 7, 2023 reviewed and approved the "Proposal on Changing the Implementation Location, Implementation Method, and Implementation Subject of Some Raised Investment Projects" and agreed to change the implementation location, implementation method, and implementation subject of the raised-fund investment project "Tuoxin Pharmaceutical Research Institute Construction Project", among which the implementation The location was changed from "Neighborhood No. 24, Xinxiang Development Zone" to "No. 99 Jianshe East Road, Xinxiang City" and "No. 515, Cologne Avenue, Xinxiang High-tech Zone"; the implementation method was changed from purchasing real estate and transforming it according to the company's needs to using the company's own assets to transform it according to the needs; the implementation entity was changed from Xinxiang Tuoxin Pharmaceutical Co., Ltd. to the wholly-owned subsidiaries Henan Nucleoside Drug Research Institute Co., Ltd. and Xinxiang Nucleoside Industry Research Institute Co., Ltd. The company's independent directors issued independent opinions in agreement, and the sponsor issued an unobjectionable verification opinion.

3. Delay of investment projects with previously raised funds

On August 23, 2024, the second meeting of the company's fifth board of directors and the second meeting of the fifth board of supervisors reviewed and approved the "Proposal on Adjusting and Extension of Construction Content of Part of the Investment Projects Raised Funds", and agreed to adjust and extend the construction content of the "Nucleoside Series Characteristic API and Pharmaceutical Intermediates Construction Project", and the date to reach the scheduled usable state was extended to September 30, 2025. The sponsor issued an unobjectionable verification opinion.

(3) Explanation of the differences and reasons between the actual total investment amount of the previous fund-raising project and the commitment

(1) The "Nucleoside Series Characteristic API and Pharmaceutical Intermediates Construction Project" has a committed investment amount of 235.4564 million yuan, and the actual investment amount is 243.215 million yuan, with a difference of 7.7586 million yuan from the committed investment amount;

(2) The "annual output of 1,000 tons of nucleoside series food nutrition fortifier project" has a committed investment amount of 59.8177 million yuan, and the actual investment amount is 61.0329 million yuan, with a difference of 1.2152 million yuan from the committed investment amount;

(3) The committed investment amount of “exceeding raised funds to supplement working capital” was RMB 88 million, and the actual investment amount was RMB 91.1469 million, with a difference of RMB 3.1469 million from the committed investment amount.

The main reason for the above difference is that in order to improve the efficiency of the use of raised funds, and without affecting the normal implementation of investment projects with raised funds and the safety of raised funds, the company used idle raised funds for cash management to obtain a certain investment income and the net amount of interest income generated during the storage period minus handling fees, etc.

(4) The "Tuoxin Medical Research Institute Construction Project" had a committed investment amount of 60 million yuan, and the actual investment amount was 39.9128 million yuan. The difference between the committed investment amount and the committed investment amount was 20.0872 million yuan. The difference was mainly due to the fact that the implementation method of the project during the construction process was finally changed from the self-construction model to the company's own assets based on demand transformation model, which significantly reduced the construction cost of the raised investment project. At the same time, the company strictly supervises, controls and manages the costs of each link of the project in line with the principles of reasonableness, economy and effectiveness, and reasonably reduces the overall investment amount of the project. In addition, under the premise of ensuring that the normal implementation of investment projects with raised funds and the safety of raised funds are not affected, the company uses idle raised funds for cash management and obtains a certain investment income and the net amount of interest income generated during the storage period minus handling fees.

(5) Closing the project and using the remaining raised funds to permanently replenish working capital: October 23, 2023, the 25th meeting of the company’s fourth board of directors, the 18th meeting of the fourth board of supervisors, and the company’s third extraordinary shareholders’ meeting in 2023 on November 9, 2023 The meeting reviewed and approved the "Proposal on Closing Part of the Investment Project with Raised Funds and Permanently Replenishing Working Capital with the Surplus Raised Funds". In view of the fact that the "Tuoxin Pharmaceutical Research Institute Construction Project" invested by the company's raised funds has reached the intended usable state and can be completed according to the implementation plan. In order to fully utilize the efficiency of fund use and maximize the effectiveness of raised funds, and based on the company's actual operating conditions, it is agreed that the company will use the remaining raised funds of RMB 22.0613 million (including bank interest, the final amount shall be based on the bank interest settlement amount on the day when the funds are transferred out) to permanently supplement working capital for the company's daily production and operation activities. The company transferred out RMB 22.00 million in November 2023 to permanently replenish working capital; on April 25, 2025, the company held the fifth meeting of the fifth board of directors and the fifth meeting of the fifth board of supervisors, and reviewed and approved the "Proposal on Closing Investment Projects with Partial Raised Funds and Permanently Replenishing Working Capital with the Surplus Raised Funds". In view of the fact that the company The fund-raising investment project "Nucleoside Series Characteristic API and Pharmaceutical Intermediates Construction Project" has reached the intended usable state and can be completed according to the implementation plan. It is agreed that the company will use the remaining raised funds of RMB 13,100 (including bank interest, the final amount shall be based on the bank interest settlement amount on the day when the funds are transferred out) to permanently supplement working capital for the company's daily production and operation activities. In view of the fact that the "Tuoxin Pharmaceutical Research Institute Construction Project", an investment project raised by the company's raised funds, has been completed, it is agreed that the unpaid balance of the project and the guarantee deposit amount of 493,900 yuan (including bank interest, the final amount shall be based on the bank interest settlement amount on the day when the funds are transferred out, and at the same time Including the 61,300 yuan that was approved at the 25th meeting of the company’s fourth board of directors and has not yet been transferred out) will be used to permanently replenish working capital. The company will subsequently use its own funds or self-raised funds to pay the unpaid contract balance and warranty deposit for the project. As of December 31, 2025, the company had transferred RMB 22,493,900 from the special account to raise funds from the "Tuoxin Pharmaceutical Research Institute Construction Project" and RMB 13,100 from the special account to raise funds from the "Construction Project of Nucleoside Series Characteristic APIs and Pharmaceutical Intermediates." The company's investment projects with raised funds had transferred a total of RMB 22,507,000 from the above-mentioned special account to permanently replenish working capital.

(6) Closing the project and permanently replenishing working capital with the surplus over-raised funds: On April 25, 2025, the company held the fifth meeting of the fifth session of the Board of Directors and the fifth meeting of the fifth session of the Supervisory Board, and reviewed and approved the "About Closing the Investment Project with Over-raised Funds and Permanently Replenishing Working Capital with the Surplus Over-raised Funds". In view of the fact that the company's investment projects with over-raised funds " The "1,000-ton annual nucleoside series food nutritional supplement project" has reached the intended usable state and can be completed according to the implementation plan. It is agreed that the company will permanently supplement the working capital of the company's daily production and operation activities by using the surplus over-raised funds of RMB 108,900 (including bank interest, the final amount shall be based on the bank interest settlement amount on the day when the funds are transferred out). As of December 31, 2025, the company had transferred a total of 108,900 yuan from the above-mentioned special account for super-raised funds to permanently replenish working capital.

(4) Explanation of external transfer or replacement of investment projects with previously raised funds

1. External transfer of investment projects with previously raised funds

The Company has no external transfer of investment projects with raised funds.

2. Replacement of investment projects with previously raised funds

On November 10, 2021, the seventh meeting of the company's fourth board of directors and the fourth meeting of the fourth board of supervisors reviewed and approved the "Proposal on Using Raised Funds to Replace Self-raised Funds for Pre-invested Projects", and agreed that the company would use the funds raised from this issuance to replace self-raised funds of RMB 4,093,300.00 for pre-invested projects. Zhongshen Zhonghuan Accounting Firm (Special General Partnership) has authenticated the company's pre-investment of self-raised funds in the company's investment projects. On November 5, 2021, it issued the "Authentication Report on the Pre-Investment of Raised Funds in Investment Projects by Xinxiang Tuoxin Pharmaceutical Co., Ltd. with self-raised funds" (Zhonghuan Special Number [2021] No. 2110030).

The company has completed the relevant procedures for replacing the pre-invested self-raised funds in December 2021.

(5) Description of idle raised funds

On November 10, 2021, the seventh meeting of the company's fourth board of directors and the fourth meeting of the fourth board of supervisors reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital", and agreed that the company will use part of the idle raised funds to temporarily supplement the company's working capital on the premise of ensuring the capital needs for the construction of investment projects and the normal progress of the raised funds use plan. The total amount shall not exceed RMB 50 million, and the period of single supplementary working capital shall not exceed twelve months; the "Proposal on the Use of Partially Idle Raised Funds for Temporarily Supplementing Working Capital" was reviewed and approved. "Proposal on Using Part of Idle Raised Funds for Cash Management", agreeing that the company intends to use no more than RMB 250 million (including the original amount) for idle purposes without affecting the normal progress of the investment plan of raised funds, the safety of funds and the company's normal production and operations. Raise funds to purchase investment products with high security, good liquidity, and capital-guaranteed agreements (including but not limited to capital-guaranteed financial products, structured deposits, agreement deposits, notice deposits, time deposits, certificates of deposit, etc.). The investment period of a single financial product shall not exceed 12 months. The validity period of cash management shall be 12 months from the date of review and approval at the seventh meeting of the fourth session of the board of directors of the company. Funds within the above quota can be used on a rolling basis within the validity period of the investment. After the cash management of temporarily idle raised funds expires, they will be returned to the special account for raised funds in a timely manner. In response to the above proposal, the company's independent directors issued independent opinions in agreement, and the sponsor issued an unobjectionable verification opinion. As of October 28, 2022, the company has returned all the raised funds temporarily used to supplement working capital to the company's special account for raised funds. As of October 21, 2022, the financial management products purchased by the company using raised funds have all expired and been redeemed, and all principal and income have been returned to the raised funds account.

On November 9, 2022, the 18th meeting of the company's fourth board of directors and the 13th meeting of the fourth board of supervisors reviewed and approved the "Proposal on Using Part of Idle Raised Funds to Temporarily Supplement Working Capital", agreeing that the company will use part of the idle raised funds to temporarily supplement the company's working capital on the premise of ensuring the capital needs for the construction of investment projects and the normal progress of the raised funds use plan, with a total amount not exceeding RMB 30 million, and a single supplementary working capital period not exceeding twelve months; the "Proposal on the Use of Partially Idle Raised Funds for Temporarily Supplementing Working Capital" was reviewed and approved. "Proposal on Using Part of Idle Raised Funds for Cash Management", agreeing that the company intends to use no more than RMB 220 million (including the original amount) for idle purposes without affecting the normal progress of the investment plan of the raised funds, the safety of funds and the company's normal production and operations. Raise funds to purchase investment products with high security, good liquidity, and capital-guaranteed agreements (including but not limited to capital-guaranteed financial products, structured deposits, agreement deposits, notice deposits, time deposits, certificates of deposit, etc.). The investment period of a single financial product shall not exceed 12 months. The cash management validity period is 12 months from the date of review and approval at the seventh meeting of the company's fourth board of directors. Funds within the above quota can be used on a rolling basis within the validity period of the investment. After the cash management of temporarily idle raised funds expires, they will be returned to the special account for raised funds in a timely manner. In response to the above proposal, the company's independent directors issued independent opinions in agreement, and the sponsor issued an unobjectionable verification opinion. As of November 9, 2023, the company has returned all the raised funds temporarily used to supplement working capital to the company's special account for raised funds. As of September 28, 2023, the financial management products purchased by the company using raised funds have all expired and been redeemed, and all principal and income have been returned to the raised funds account.

On October 23, 2023, the 25th meeting of the company's fourth board of directors and the 18th meeting of the fourth board of supervisors reviewed and approved the "Proposal on Using Part of Idle Raised Funds for Cash Management", agreeing that on the premise of ensuring the funds required for the company's investment projects and ensuring the safety of the raised funds and the company's normal production and operation activities, the company can use temporarily idle raised funds in an amount not exceeding RMB 50 million to purchase security. Investment products (including but not limited to capital-guaranteed financial products, structured deposits, agreement deposits, notice deposits, time deposits, certificates of deposit, etc.) that are highly liquid, have a capital guarantee agreement and have an investment period of no more than 12 months are valid for 12 months from the date of approval by the company's board of directors. Funds within the above quota can be used on a rolling basis within the investment validity period. Temporarily idle raised funds will be returned to the special raised funds account in a timely manner after the expiration of cash management. The company's independent directors issued independent opinions in agreement, and the sponsor issued an unobjectionable verification opinion. As of February 23, 2024, the financial management products purchased by the company using raised funds have all expired and been redeemed, and all principal and income have been returned to the raised funds account.

3. Explanation of the benefits achieved by investment projects with previously raised funds

(1) Comparison table of benefits achieved by investment projects with previously raised funds

Please see Annex 2 of this report for a comparison table of the benefits achieved by the investment projects with previously raised funds.

The calculation caliber and calculation method of realized benefits in the comparison table are consistent with the calculation caliber and calculation method of promised benefits.

(2) Explanation of the situation where the benefits of investment projects with previously raised funds cannot be separately calculated

The company's previous investment project with raised funds, "Tuoxin Pharmaceutical Research Institute Construction Project", "supplementing working capital", "closing the project and using the surplus raised funds to permanently replenish working capital" and "closing the project and using the surplus raised funds to permanently replenish working capital" do not produce direct economic benefits, and the benefits cannot be calculated separately.

(3) Explanation that the cumulative realized income from the investment project with previously raised funds is lower than the promised cumulative income

The investment projects raised with funds, "Nucleoside Series Characteristic APIs and Pharmaceutical Intermediates Construction Project" and "Annual Production of 1,000 Ton Nucleoside Series Food Nutritional Enhancers Project" will reach the scheduled usable status in June 2025. As the project is in the stage of ramping up production capacity, scale benefits have not yet been fully released; combined with intensified industry competition and changes in the market supply and demand pattern, the company has adjusted the production schedule of some products, and the production capacity utilization rate of related products has not reached the optimal level, resulting in the actual benefits of the project being less than expected.

4. Description of the operation of assets involving the subscription of shares with assets in the previous issuance

The company did not use assets to subscribe for shares in its previous fundraising.

5. Comparison of the actual use of funds raised in the previous round and the publicly disclosed information

As of December 31, 2025, there is no difference between the actual use of the company's previous raised funds and the content in the company's annual periodic reports and other information disclosure documents.

Attachments:

1. Comparison table of usage of funds raised last time

2. Comparison table of benefits achieved by investment projects with previously raised funds

(This page has no text)

Tuoxin Pharmaceutical Group Co., Ltd. Board of Directors

May 13, 2026

Attachment 1

Comparison table of usage of funds raised last time

As of December 31, 2025

Prepared by: Tuoxin Pharmaceutical Group Co., Ltd. Unit: 10,000 yuan

Total raised funds: 54,327.41 Total accumulated raised funds used: 55,792.35

The total amount of raised funds used in each year:

Total funds raised for change of purpose: 0.00 2021: 13,088.86 2022: 13,348.11

2023: 25,509.44 Proportion of total raised funds changed use: 0.00% 2024: 3,759.73 2025: 86.22 Investment projects Total investment of raised funds Cumulative investment amount of raised funds on the deadline

The project reaches the predetermined actual investment amount and

Usage status date/or

Commitment after fundraising Actual

Preface Commitment to invest before fundraising Commitment after fundraising Actual Commitment before fundraising Commitment to invest after fundraising

Project completion deadline

Commitment investment project Actual investment project Investment amount Investment amount

No. Amount Investment amount Investment amount Investment amount Difference between amounts

Degree ① ②

③=②-①

Nucleoside Series Featured Raw Materials Nucleoside Series Featured Raw Materials

1 Pharmaceutical and pharmaceutical intermediate construction Pharmaceutical and pharmaceutical intermediate construction 23,545.64 23,545.64 24,321.50 23,545.64 23,545.64 24,321.50 775.86 June 2025

Set up project Set up project

Tuoxin Pharmaceutical Research Institute was built Tuoxin Pharmaceutical Research Institute was built

2 6,000.00 6,000.00 3,991.28 6,000.00 6,000.00 3,991.28 -2,008.72 October 2023

Set up project Set up project

3 Supplementary working capital Supplementary working capital 10,000.00 10,000.00 10,000.00 10,000.00 10,000.00 10,000.00 Not applicable

Close the project and raise the remaining balance. Close the project and raise the remaining balance.

4 Permanent replenishment of funds Permanent replenishment of funds 2,250.70 2,250.70 2,250.70 Not applicable

funds funds

5 Over-raised funds to supplement working capital 8,800.00 9,114.69 8,800.00 9,114.69 314.69 Not applicable

Annual output of 1,000 tons of nucleoside systems

6 Excess funds raised List of food nutrition fortifiers 5,981.77 6,103.29 5,981.77 6,103.29 121.52 Project in June 2025

Close the project and overfund the savings

7 Over-raised funds Permanent replenishment of funds 10.89 10.89 10.89 Not applicable funds

Total 39,545.64 54,327.41 55,792.35 39,545.64 54,327.41 55,792.35 1,464.94

Attachment 2 Comparison table of benefits achieved by investment projects with previously raised funds

As of December 31, 2025

Prepared by: Tuoxin Pharmaceutical Group Co., Ltd. Unit: 10,000 yuan

Actual investment projects Actual benefits in the past three years

Investment projects on the deadline. Accumulated actual performance on the deadline. Whether the pre-committed benefits have been achieved.

Cumulative capacity utilization rate Current benefit Calculated benefit serial number Project name 2025 2024 2023

Nucleoside series of specialty raw materials and medicines will achieve average annual net profit after reaching production.

1 25.78% -694.74 -694.74 No

Pharmaceutical intermediates construction project 65.327 million yuan

2 Tuoxin Medical Research Institute Construction Project Not applicable Not applicable 3 Supplementary working capital —— Not applicable Not applicable

The project will be closed and the remaining funds raised will be used forever——

4 Not applicable Not applicable

Long-term replenishment of working capital

5 Supplementary working capital - Not applicable Not applicable

Annual output of 1,000 tons of nucleoside series foods, achieving average annual net profit after reaching full production

6 8.39% -968.41 -968.41 No Nutritional fortifier project 73.8373 million yuan

The project will be closed and the remaining funds will be used permanently—

7 Not applicable Not applicable Long-term replenishment of working capital

Note: After the completion of the over-raised capital investment project "1,000-ton annual nucleoside series food nutrition fortifier project", in order to meet the company's business and product development plans and improve equipment utilization efficiency, the company carried out technical transformation and upgrades to the project's production line. Since the new equipment is used in conjunction with the original equipment of the project, the benefits of the over-raised project cannot be calculated separately. The benefit indicators disclosed here are the overall operating benefits of the project implementation entity.